Renovacor Reports Second Quarter 2022 Financial Results and Provides Corporate Update
REN-001 IND submission planned for the second half of 2022Data from pilot pig study showing successful cardiac transduction with REN-001 delivered via low-dose retrograde coronary sinus infusion published in Journal of the American College of Cardiology: Basic to Translational ScienceCAMBRIDGE, Mass.--(BUSINESS WIRE...
United States United Kingdom Patrick Bursey Magdalene Cook Renovacor Inc Securities Exchange Commission
Source: pharmiweb.com